You're spot on. At only 3 cents, the tiny market capital of barely 7 million gives the share price so much room to grow. Today's good news - HREC approval - means the gates of news flow are now officially open.
For a company about to start an exciting opioid alternative phase 2 trial that is fully funded, the current share price is dirt cheap. I've seen several ASX peers in recent years comfortably hit 700 million in market capital on hype alone.
Today's cost is 7 million. Let that sink in.
With the low shares on issue, all clinical funding secured, & news flow ready to roll, imho this small nugget has thriving conditions for serious share price growth.
GLTAH
Add to My Watchlist
What is My Watchlist?
